In the quarter preceding the change in regulatory guidance, 33 patients (39.8%) with advanced squamous NSCLC without evidence of PD-L1 testing, 7 (29.2%) with negative (0%) PD-L1 staining, and 20 (36.4%) with PD-L1 expression of 1% to 49% received first-line ICI treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.